Abbott India Limited has signed a non-exclusive patent license agreement with Takeda Pharmaceuticals to market and distribute the novel gastrointestinal therapy, Vonoprazan (branded as Vonefi), in India, which offers a once daily dose for severe acid-related disorders, improving patient compliance.